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Clinical high-risk (CHR) individuals have been increasingly utilized to investigate the 
prodromal phases of psychosis and progression to illness. Research has identified medial 
and lateral temporal lobe abnormalities in CHR individuals. Dysfunction in the medial 
temporal lobe, particularly the hippocampus, is linked to dysregulation of glutamate 
and dopamine via a hippocampal–striatal–midbrain network that may lead to aberrant 
signaling of salience underpinning the formation of delusions. Similarly, lateral temporal 
dysfunction may be linked to the disorganized speech and language impairments 
observed in the CHR stage. Here, we summarize the significance of these neurobiological 
findings in terms of emergent psychotic symptoms and conversion to psychosis in CHR 
populations. We propose key questions for future work with the aim to identify the neural 
mechanisms that underlie the development of psychosis.
Keywords: schizophrenia, temporal lobe, clinical high risk, hippocampus, dopamine, glutamate
INTRODUCTION
Over the last few decades, early clinical interventions for people with psychosis have become more 
widespread, with an increasing clinical and research interest in identifying people presenting with 
early signs and symptoms of psychosis (1). Globally, a number of clinical services have been established 
that are aimed at preventative interventions. Such services identify people, usually young help-seeking 
individuals, experiencing prodromal symptoms characterized by attenuated psychotic symptoms (APS), 
including perceptual disturbances (subthreshold hallucinations) and overvalued ideas (subthreshold 
delusions), a brief psychotic episode, or exhibit a decline in social and occupational function coupled 
with familial risk (2). Individuals meeting one or more of these criteria are considered to be at a clinical 
high risk (CHR) for psychosis (2, 3), and around 20% will develop an onset of first-episode psychosis 
(FEP) within 1 to 2 years (with transition rates varying from 18% at 6-month follow-up to 36% after 3 
years) (1). In addition to putative clinical benefits associated with early identification and intervention, 
research into early and prodromal phases of the illness may provide important information about the 
pathology of psychosis that is not confounded by long-term medication and/or illness chronicity. One 
approach is to longitudinally track neural changes using neuroimaging techniques such as magnetic 
resonance imaging (MRI) and positron emission tomography (PET). In 2002, Philips and colleagues 
(4) published the first neuroimaging study in a CHR population, reporting changes in hippocampal 
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volume relative to age-matched healthy controls. This deficit 
neatly echoes the findings from meta-analyses in schizophrenia 
patients showing that the structure with greatest volume 
reduction compared to healthy individuals across the brain is the 
hippocampus (as well as amygdala and parahippocampus) (5, 6). 
Since then, several MRI studies [e.g., Refs. (7–10)] along with 
several PET studies [e.g., Refs. (11–14)] in CHR cohorts have been 
published, reporting a range of findings relating to brain function 
and connectivity, anatomy, and chemistry. While neuroimaging 
studies report neuroanatomical and neurofunctional changes 
across a range of cortical, subcortical, and cerebellar areas, 
neurobiological changes in two temporal lobe regions seem to 
feature prominently in the neurobiological basis of psychosis and 
the CHR state, namely, the medial temporal lobe (MTL) [e.g., 
Refs. (8, 15–20)] and the lateral temporal cortices [e.g., Refs. 
(21–24)]. Moreover, preclinical models [see Refs. (9, 25)] propose 
that neurobiological changes in temporal lobe regions may occur 
early in the developmental trajectory of psychosis and have 
a particular role in the development of attenuated psychotic 
symptoms (APS).
Furthermore, guided by work in animal models of 
schizophrenia (25–27) and findings from neuroimaging studies 
in patients with established schizophrenia, nascent neuroimaging 
research in CHR populations has identified the importance of 
an MTL and subcortical network involving the hippocampus, 
midbrain, and striatum (8, 9). Meanwhile, a separate body of 
neuroimaging work in CHR cohorts, again informed to a large 
extent by research in patients with established schizophrenia, 
has identified functional and anatomical alterations in the lateral 
temporal cortex and broader networks involving the frontal and 
parietal lobes (24, 28).
Given the role that progressive neurobiological changes in 
medial and lateral temporal lobe regions appear to play in the 
development of psychosis, we review evidence supporting 
dysfunction in temporal lobe-centered networks in people at 
CHR for psychosis and discuss how putative dysfunction in 
these regions and networks relates to the emergence of APS. We 
also consider how dysfunction and progressive changes in these 
regions track with conversion from the APS observed in CHR to 
first-episode psychosis (FEP).
CLINICAL HIGH-RISK SYMPTOMS 
AND THE ONSET OF PSYCHOSIS
Prodromal symptoms are operationalized into criteria for 
a CHR state and are assessed using instruments such as the 
Comprehensive Assessment of At Risk Mental State (CAARMS) 
(29, 30) and the Structured Interview for Prodromal Symptoms/
Scale of Prodromal Symptoms (SIPS/SOPS) (31). The criteria 
apply to young help-seeking individuals and require one of the 
following presentations: i) attenuated psychotic symptoms (APS), 
i.e., subthreshold delusions, hallucinations, and thought and 
language disturbances for which insight is preserved, ii) threshold 
psychotic symptoms that are brief and self-limiting, and iii) a 
significant decrease in functioning in the context of schizotypal 
personality disorder (SPD) or genetic risk for schizophrenia 
(32). Additional prodromal criteria may include subjective 
disturbances of cognitive processing and the perception of the 
self and the world (33, 34) and nonpsychotic symptoms such as 
anxiety and depression (35). More than 90% of CHR individuals 
present with APS, in particular attenuated delusions of unusual 
thought content and suspiciousness (36). While APS are almost 
always present in CHR individuals at clinical presentation, 
factor analytical studies of the CAARMS assessment instrument 
report a “disorganized symptoms” dimension that includes 
disorganized speech and thought, which is the best predictor of 
later conversion to FEP (37, 38), a finding also identified using 
the SIPS/SOPS (39–42).
Taken together, these symptom studies in CHR cohorts 
might suggest a pattern in which attenuated delusional ideation 
characterizes nearly almost all CHR cases, while disturbance in 
thought and language is more characteristic of those CHR cases 
that later develop psychosis. Is there any neuroimaging evidence 
to support this view, and what are the implications of these 
symptom patterns for emerging brain network dysfunction in 
CHR cohorts?
MEDIAL TEMPORAL LOBE NETWORK
While a range of neurobiological changes are identified in 
people with schizophrenia, including enlarged ventricles and 
volumetric reductions in the frontal lobes, thalamus, amygdala, 
hippocampus, and lateral temporal cortex (5, 43, 44), two 
neurobiological findings appear to be particularly robust. First, 
there are neuroanatomical and physiological alterations in 
the hippocampus and medial temporal lobe (MTL) (45–48) 
and second, elevated dopamine function in the midbrain and 
striatum [see Ref. (49) for review].
Based on decades of neuroimaging work describing anatomical, 
functional, and physiological changes in the hippocampus and 
MTL [e.g., Refs. (8, 10, 15, 17, 50)], in recent years, a number 
of researchers have developed a pathophysiological model 
that characterizes the progression of schizophrenia from the 
premorbid through the prodromal stages to syndromal psychosis. 
This model posits dysregulation of glutamate neurotransmission 
occurring in the CA1 region of the hippocampus that elevates 
neuronal activity, reflected in metabolism and blood flow, and 
in doing so elicits the APS emerging in the prodromal stage of 
schizophrenia (8, 19). As glutamate-driven dysregulation of the 
CA1 region of the hippocampus persists, dysfunction expands 
to projection fields within and external to the hippocampus and 
frontal cortex, leading to onset of threshold psychosis. According 
to this heuristic, as the illness progresses, an atrophic process 
ensues in which the neuropil of hippocampal cells is reduced, 
compromising numbers of interneurons, and leading to the 
volumetric reduction in the MTL and other regions observed in 
patients with schizophrenia (8, 19).
In line with this model, there is evidence from a number of 
neuroimaging studies of reduced hippocampal gray matter in 
CHR cohorts. Cross-sectional studies comparing CHR subjects 
to healthy controls have reported reduced gray matter volume 
in the hippocampal and surrounding MTL (4, 21,  51,  52), 
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altered hippocampal function during word recognition (16), and 
elevated resting hippocampal perfusion (18, 53). Furthermore, 
prospective and longitudinal studies that include CHR 
subgroups who develop psychosis subsequent to scanning show 
that hippocampal volume, function, and perfusion changes can 
predict conversion to psychosis in CHR cohorts (8, 10, 15, 50, 54). 
However, it must be noted that there are negative studies too; see 
meta-analysis by Ref. (55). Within the MTL, reductions in volume 
and altered function have been localized to the anterior part of 
the hippocampus/parahippocampal gyrus (15, 50). A study by 
Schobel and colleagues (8) found that resting regional cerebral 
blood volume (CBV), a measure of metabolism and neuronal 
activity, was increased in the CA1 region of the hippocampus 
at baseline in CHR subjects who later developed psychosis. 
Moreover, longitudinal follow-up in this CHR cohort showed 
that the onset of psychosis was associated with a progressive 
increase in resting CBV in the anterior hippocampal subiculum 
that tracked with gray matter volume reduction in the same MTL 
region (8, 56).
That CA1 CBV is elevated in CHR prior to psychosis onset, 
and hippocampal subiculum CBV is elevated after onset, points 
to the progressive nature of hippocampal deficits in CHR that are 
associated with psychosis—and also offers a locus of enquiry as 
to how these two separate hippocampal regions may additively 
or differentially contribute to psychosis development in CHR. It 
is noteworthy that the subiculum is the primary output structure 
of the hippocampus (57), and also that the nucleus accumbens/
ventral striatum receives its strongest excitatory input from 
the ventral subiculum—consistent with the central role of the 
ventral hippocampus in driving dopaminergic changes in the 
rodent model discussed below (25). The model proposed in the 
study by Schobel and colleagues (8) also posits that changes in 
hippocampal CBV during this pathophysiological process are 
driven by glutamate dysregulation. There is substantial evidence 
that glutamate is altered in schizophrenia and psychosis risk 
states (58–61). More recently, a prospective study by Bossong and 
colleagues (20) reports increased hippocampal glutamate levels 
in CHR subjects who later developed psychosis relative to CHR 
subjects who did not become psychotic. Additionally, ketamine, 
an N-methyl-D-aspartate (NMDA) receptor antagonist used as 
a model of schizophrenia, specifically raises CBV and glutamate 
levels in both CA1 and subiculum subregions of mouse 
hippocampus (8). By contrast, glutamate levels are generally 
reduced in medicated schizophrenia patients (62), together, 
suggesting that increased glutamate levels in the hippocampus 
may be more closely tied to the development and/or presence of 
symptoms rather than of a diagnosis of schizophrenia per se.
Given these findings, how might glutamate-driven dysregulation of 
hippocampal or MTL physiology relate to elevated striatal and 
midbrain dopamine? Experimental work in rodents illustrates 
how changes in these two neurotransmitter systems might be 
linked and contribute to the development of psychosis. Studies 
in rats show that lesions or local glutamate receptor modulation 
activation of the ventral hippocampus leads to changes in the 
activity of midbrain Dopamine (DA) neurons and striatal 
DA release [e.g., Refs. (63, 64)]. Subsequently, several rodent 
disease models developed with the aim of recapitulating 
schizophrenia-relevant developmental neuropathology have 
supported strong links between hippocampal pathology, 
altered basal hippocampal activity, and dysregulation of 
midbrain dopamine neurons. One of the earliest of these 
models showed that bilateral excitotoxic lesions of the ventral 
hippocampus on postnatal day 7 in the rat altered excitatory 
activity in the hippocampus and produced changes to striatal 
dopamine markers (65, 66). In another well-characterized 
model, the MAM E17 rat, perturbation of neurodevelopment 
by administration of methylazoxymethanol acetate (MAM) 
to pregnant rats on embryonic day (E) 17 was associated with 
a number of histological, neurophysiological, and cognitive/
behavioral deficits in the offspring that are analogous to those 
observed in some schizophrenia patients (25, 26). The most 
prominent histological abnormalities in the MAM E17 model 
appear in the hippocampus, including a reduction in the 
thickness and deficit in parvalbumin-expressing (PV+) gamma-
Aminobutyric acid (GABA) ergic inhibitory interneurons. 
The MAM E17 model has highlighted the potential role of a 
hippocampal–midbrain–striatal circuit in the development 
of striatal dopamine dysregulation that, in turn, could drive 
the emergence of APS and psychosis. In this model, midbrain 
dopamine neuron activity and striatal dopamine levels are 
elevated (25, 26, 67), possibly as a consequence of aberrant 
hippocampal drive of ventral striatal projections (25, 26, 67) 
(see Figure 1). Indeed, inactivation of ventral hippocampus 
in MAM mice completely reversed the elevated dopamine 
activity (68). Of note, the elevation of ventral hippocampal 
activity raises not only tonic dopamine, but further, aberrant 
responsivity of the dopamine system phasically (68).
Complementary work in a genetic mouse model of a 
selective PV+ interneuron deficit in the hippocampus further 
supports a role for hippocampal dysregulation of striatal DA 
inputs (69). Deletion of the cyclin D2 gene during embryonic 
development leads to a reduction in PV+ interneurons destined 
for the hippocampus. As adults, these mice show a selective, 
partial (40–50%) reduction in hippocampal PV+ interneuron 
density and decreased hippocampal thickness. Application of 
gadodiamide-enhanced contrast MRI to this model showed 
increased resting CBV in the hippocampus, similar to the 
imaging phenotype observed in CHR cases that convert to 
psychosis within 2 years (8). Neurophysiological studies show 
that, in adulthood, cyclin D2 null mice show a deficit in inhibitory 
synaptic inputs onto hippocampal projection neurons, which 
is concurrent with excessive activity in midbrain/ventral 
tegmental area (VTA) dopamine neurons. Moving beyond 
descriptive and correlational studies, a seminal stem-cell 
transplant study in the cyclin D2 null mouse and MAM E18 
rat established a causal link between hippocampal disinhibition 
and excess activity of midbrain dopamine neurons. Specifically, 
restoring/supplementing GABAergic interneuron numbers 
in the hippocampus in adulthood through transplantation of 
PV+ interneuron precursor cells from the embryonic medial 
ganglionic eminence in these models, reduces metabolic 
activity in the hippocampus (69) and normalizes both the spike 
activity of the midbrain DA neurons and behaviors mediated by 
striatal DA transmission (70).
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Consistent with the above animal models of schizophrenia 
highlighting abnormal hippocampal disinhibition, Allen and 
colleagues (18) reported increased resting cerebral blood flow 
(rCBF) across hippocampal, striatal, and midbrain regions in 
a CHR cohort relative to healthy controls [using an magnetic 
resonance (MR) perfusion measure known as arterial 
spin labeling] (71), a finding largely replicated in a second 
independent CHR cohort (53). Further, longitudinal analysis 
showed that normalization of hippocampal rCBF tracked with 
clinical improvement of symptoms in the CHR cohort, while 
elevated hippocampal rCBF persisted in those who remained 
symptomatic or developed psychosis (18).
To summarize, guided by work in experimental animals, the 
available evidence in humans, although limited, points toward 
emerging network dysfunction in a hippocampal–striatal–
midbrain network that is driven by glutamate dysregulation 
resulting in disrupted hippocampal physiology, function, 
and eventually reduced volume. Furthermore, increased 
hippocampal neural activity leads to dysregulation of striatal–
midbrain dopamine signaling. How dysfunction in this 
network relates to APS and conversion to FEP is discussed in 
more detail later (section Discussion: Emerging Temporal Lobe 
Dysfunction in Clinical High-Risk Populations, Attenuated 
Symptoms, and Transition to Psychosis). Currently however, 
most clinical studies investigate only one neurobiological 
component of the preclinical models discussed above. Clearly, 
to test preclinical models more rigorously, there is a need for 
more multimodal neuroimaging work that can better integrate 
information about neurochemical, physiological, functional, 
and anatomical factors.
LATERAL TEMPORAL LOBE NETWORK
Disordered brain connectivity is thought to be a central 
pathophysiological feature of schizophrenia (72–75). 
The disconnection  hypothesis of  schizophrenia was initially 
motivated by neuroimaging studies showing abnormal 
patterns of functional connectivity between lateral temporal 
and frontal lobe regions (76–80). Lateral temporal and frontal 
lobe networks are important for a range of cognitive functions, 
particularly speech, thought, and language [see Ref. (81)]. 
The language network usually refers to the superior temporal 
gyrus (STG), middle temporal gyrus (MTG), the superior 
temporal sulcus (STS), the inferior frontal gyrus (IFG), frontal 
operculum, and adjacent regions in the inferior parietal lobe of 
both hemispheres, but with lateralization to the left hemisphere 
(82, 83) (see Figure 2).
Dysfunction in lateral temporal-centered networks in 
patients with schizophrenia is thought to underlie positive 
symptoms relating to language, thought, and speech such 
as auditory verbal hallucinations (10, 84–86) and thought 
disorder (87). To date, there are a limited number of studies 
suggesting altered function and connectivity in this network 
during prodromal stages of illness (22–24, 28). In a cross-
sectional study, Crossley et al. (22) studied participants with 
CHR for psychosis, FEP patients, and healthy controls using a 
working memory task. Effective connectivity between frontal 
and temporal lobe regions was explicitly examined. There 
were differences in effective connectivity between the STG 
and prefrontal regions across the three groups, with a negative 
coupling between these areas in controls, a positive coupling 
FIGURE 1 | Diagram showing hippocampal midbrain striatal circuit involved in the regulation of striatal dopamine via glutamatergic, GABAergic projections (+) = 
excitatory pathway and (−) = inhibitory pathway. In schizophrenia and clinical high-risk (CHR) states, it is hypothesized that increased glutamatergic output from the 
hippocampal subiculum to the ventral striatum (blue pathway) reduces inhibition via glutamatergic and GABAergic pathways that ultimately drives ventral tegmental 
area (VTA) dopamine cells and dopamine release back to the striatum (red pathway).
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in the FEP group, and intermediate effective connectivity 
parameters seen in the CHR group. In both the FEP and CHR 
groups, altered effective connectivity was accompanied by 
increased task-related STG activity. The authors concluded 
that a failure to deactivate the STG during tasks that engage 
the prefrontal cortex is already evident at psychosis onset 
and may reflect a disruption of frontal and lateral temporal 
connectivity in psychosis. These connectivity changes, albeit to 
a lesser extent, were also seen in the CHR stage (22). Also using 
a cross-sectional study design, Allen and colleagues (75) used 
the Hayling Sentence Completion Task (HSCT) to examine 
frontal and lateral temporal lobe connectivity in a CHR group. 
During the HSCT, the CHR group did not differ from healthy 
controls in terms of frontal or temporal activation. However, 
there was greater anterior cingulate cortex (ACC) activity 
in the CHR participants during incongruent HSCT trials. 
Effective connectivity analysis revealed intact task-dependent 
modulation of frontal to temporal effective connectivity in 
the CHR group, although endogenous connection strength 
between the ACC and the MTG was increased relative to healthy 
controls. The authors concluded that frontal and temporal 
functional integration in CHR states is intact, but may depend 
on increased engagement of the ACC, an effect not observed in 
healthy controls.
Using a prospective design, Sabb and colleagues (23) 
investigated language processing and underlying neural 
networks associated with discourse processing in a CHR group. 
CHR participants and healthy controls underwent Functional 
magnetic Resonance Imaging (fMRI) while performing a 
naturalistic discourse-processing paradigm. CHR participants 
were followed for 24 months post fMRI scanning to assess 
symptom severity and social outcome. Relative to controls, 
CHR participants showed increased neural activity in a network 
of language-associated brain regions, including the medial 
prefrontal cortex bilaterally, left IFG and MTG, as well as the 
anterior cingulate cortex (ACC). Further, increased activity in 
the left IFG, STG, and caudate predicted subsequent transition 
to psychosis in CHR subjects. Within the CHR sample, severity 
of thought disorder at follow-up was positively correlated with 
signal change in the left IFG, superior frontal gyrus, and left 
MTG.
Colibazzi and colleagues (24) also use a prospective design 
with data-driven approaches to resting-state fMRI data to 
examine resting functional connectivity in a CHR group. 
Multivariate analyses revealed between-group differences in 
whole-brain connectivity patterns in bilateral temporal areas, 
mostly affecting functional connections to the thalamus. 
The study shows that the established functional connectivity 
abnormalities in temporal lobe areas, observed in schizophrenia 
patients, are also present in the CHR period, with aberrant 
connectivity of the temporal cortex predictive of transition to 
psychosis in this CHR cohort.
A more recent prospective study investigating broader 
network organizations in a CHR cohort identified abnormal 
connectivity (88) in a cerebello-thalamo-cortical circuit and 
abnormal modular connectome organization (28) in CHR cases 
that later converted to psychosis. While these studies did not 
specifically set out to examine lateral temporal lobe connectivity, 
Collin et al. (28) reported that the brain regions implicated in 
early-course schizophrenia, including the STG, were most 
abnormal in terms of connectivity. Together, these functional 
imaging studies provide evidence of altered lateral temporal lobe 
FIGURE 2 | Lateral temporal and frontal network encompassing the inferior frontal gyrus (IFG) (green), the superior frontal gyrus (SFG) (light blue), the Middle Frontal 
Gyrus (MFG) (red), the superior temporal gyrus (STG) (yellow), and the middle temporal gyrus (MTG) (blue). Networks identified via WFU_PickAtlas toolbox for 
SPM12 in Montreal Neurological Insitute (MNI) space.
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activity and connectivity in the prodromal phase of psychosis 
and that altered connectivity in temporal lobe areas predicts the 
later onset of FEP.
In addition to the functional studies discussed above, 
volumetric and diffusion tensor imaging (DTI) studies in CHR 
cohorts also report changes in frontal and temporal regions. 
In their cross-sectional analysis, Borgwardt and colleagues 
(21) report significant volumetric differences between CHR 
and healthy control groups in the left STG, as well as in the 
insula and cingulate gyrus. A prospective comparison of CHR 
participants based on their clinical outcomes at follow-up 
(approximately 2 years) revealed that those who later developed 
psychosis had less gray matter in the STG and frontal regions 
in the right insula and IFG than those who did not develop 
psychosis. These findings are in line with an earlier prospective 
volumetric study (50) that also reported that conversion to 
FEP in a CHR cohort was associated with reduced gray matter 
volume in lateral temporal and inferior frontal regions.
However, a later longitudinal volumetric study in a larger 
CHR cohort (89) reported that CHR subjects who developed 
psychosis demonstrated a greater rate of gray matter loss only 
in prefrontal cortex regions relative to CHR nonconverters and 
healthy subjects with no volumetric differences in temporal 
lobe regions. Diffusion tensor imaging (DTI) studies in 
CHR cohorts have also produced mixed results. A systematic 
review by Vijayakumar and colleagues (90) included 12 studies 
examining white matter connectivity changes in the CHR 
stage. The review reports that although the exact location of 
white matter abnormalities remains uncertain, altered white 
matter connections in frontal–lateral temporal and fronto-
limbic pathways, including the superior longitudinal and 
uncinate fasciculus, cingulum and corpus callosum, appear to 
be implicated in the CHR stage.
In summary, there is evidence for altered lateral temporal 
activity and/or connectivity and reduced volume in people 
with a CHR for psychosis. Despite the mixed and negative 
findings regarding lateral temporal (STG) connectivity [i.e., 
Refs. (22, 75)], a recent large CHR study has implicated 
altered connectivity in lateral temporal region, particularly in 
the CHR cases that later convert to psychosis (28). Volumetric 
studies in CHR cohorts, while robustly reporting reduced 
gray matter volume in frontal regions, suggest that reduced 
volume in lateral temporal lobe may also predict those CHR 
cases that convert to psychosis. Studies of structural white 
matter connectivity using DTI do report altered white matter 
in pathways connecting lateral temporal and frontal regions 
in the CHR stage. Taken together, the limited evidence to date 
suggests that changes in lateral temporal volume, function, 
and connectivity are present in the CHR stage and may also 
predict conversion to psychosis (see section Discussion: 
Emerging Temporal Lobe Dysfunction in Clinical High-
Risk Populations, Attenuated Symptoms, and Transition to 
Psychosis). However, much more work is needed to confirm 
these findings and to understand how changes in lateral 
temporal lobe-centered networks relate to APS in CHR 
cohorts, particularly disorganized speech and language 
symptoms.
DISCUSSION: EMERGING TEMPORAL 
LOBE DYSFUNCTION IN CHR 
POPULATIONS, ATTENUATED 
SYMPTOMS, AND TRANSITION  
TO PSYCHOSIS
Taken together, neuroimaging studies in CHR cohorts suggest 
that structural and functional changes are seen in both medial and 
lateral temporal lobe regions and related cortical and subcortical 
networks. We will now consider how these neurobiological 
changes relate to APS and how dysfunction in these networks is 
associated with conversion to psychosis.
Are Different Attenuated Psychotic 
Symptoms Related to Dysfunction in 
Different Temporal Lobe Networks?
The studies discussed above point to emerging structural and 
functional alterations in medial and lateral temporal lobe 
networks in people at CHR for psychosis. So, are different 
(attenuated) psychotic symptoms in the CHR stage associated 
with dysfunction in different brain networks? One of the most 
influential neurobiological models of psychosis proposes that the 
inappropriate attribution of salience, to what would normally 
be irrelevant or neutral stimuli or experiences, underlies the 
formation of delusions (91). In support of this model, increased 
hippocampal activity is reported in CHR groups in response 
to neutral relative to emotional stimuli, suggesting impaired 
salience processing (92). Further, dopamine has a central role in 
mediating salience, and hyperdopaminergic states can lead to the 
aberrant assessment of salience (91, 93). To better understand 
the bio-behavioral significance of altered hippocampal neuronal 
activity in CHR cohorts, Modinos and colleagues (Modinos et 
al., 2019) used a novelty salience task in CHR participants and 
healthy controls. In CHR individuals, the hippocampal response 
to novel stimuli was significantly attenuated compared to that 
in the control group, possibly due to increased hippocampal 
activity at rest or in the control condition, consistent with 
previous findings of increased hippocampal rCBF (18, 45, 
46). Modinos and colleagues also performed an effective 
connectivity analysis on these functional data and revealed that 
stimulus novelty (salience) modulated connections from the 
hippocampus to the ventral striatum significantly more in CHR 
participants than in controls, a finding seemingly consistent 
with the notion of increased hippocampal signaling/output 
to the striatum in psychosis (25). Conversely, stimulus novelty 
modulated connectivity from the midbrain (VTA) to the ventral 
striatum was significantly less in CHR participants than in 
HC, particularly in those CHR participants who subsequently 
developed psychosis at clinical follow-up. This pattern of activity 
and disconnectivity would be in line with the maximal tonic 
activation of dopamine neuron firing that is hypothesized to 
occur in psychosis, thought to obscure salience-driven increases 
in population activity of meso-striatal dopamine neurons (94) 
(see Figure 3A). A consequence of this might be the aberrant 
assignment of stimulus salience.
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Previous neuroimaging studies of motivational and reward 
salience processing also suggest salience dysregulation and altered 
activation within a hippocampal–striatal–midbrain network in 
people at CHR for psychosis (95–97). Using a salience attribution 
task, Roiser and colleagues (97) found that CHR individuals 
were more likely to attribute motivational salience to irrelevant 
stimulus features and this bias was related to the severity of their 
delusion-like symptoms. Moreover, ventral striatal responses to 
irrelevant stimulus features were also correlated with delusion-like 
symptoms in CHR participants. Winton-Brown and colleagues 
(95) report that reward-induced modulation of connectivity 
from the ventral striatum/pallidum to the midbrain was greater 
in CHR participants than controls, and that in CHR participants, 
the strength of connectivity in this pathway is correlated 
with the severity of their abnormal beliefs. Collectively, these 
studies suggest that the behavioral consequence of emerging 
hippocampal–striatal–midbrain network dysregulation is 
aberrant salience processing that underlies delusional formation 
in the psychosis prodrome. Furthermore, these functional and 
connectivity findings in human CHR cohorts provide support 
for preclinical work positing that hippocampal hyperactivity 
(19, 26) results in perturbed striatal function (9, 25). This is 
important because taken together, these preclinical and human 
studies identify mechanisms and processes that lead to the 
development of psychotic symptoms, potentially identifying 
targets for intervention. Indeed, understanding the sequence 
of these pathological events, i.e., glutamatergic/GABAergic 
dysregulation, hippocampal hyperactivity, striatal dopamine 
dysregulation, that lead to aberrant salience and delusional 
formation, is crucial in the development and refinement of new 
treatments.
Disorganization in thought and language (37–42) is also 
observed in CHR individuals, and form part of the APS 
operational criterion for the assignment of a CHR state. 
Decades of neuroimaging research in people with schizophrenia 
have largely linked these symptoms to dysfunction, not in a 
hippocampal–striatal–midbrain network, but instead to altered 
function in lateral temporal regions and connectivity in lateral 
temporal, frontal, and parietal networks (Figure 3B). While there 
has been less research in CHR cohorts aimed at studying lateral 
temporal networks (23–28), their dysfunction, and relationship 
to symptoms, there are a large number of neuroimaging studies 
in established schizophrenia patients reporting that lateral 
temporal dysfunction and disconnectivity are associated with 
disorganized speech and language [see Ref. (87) for review] 
and auditory verbal hallucinations (10, 84, 85). It is tempting to 
speculate that these symptoms, ostensibly based around language 
and sensory dysfunction, have a different neurobiological basis 
than those relating to aberrant salience. Given that disorganized 
symptoms appear to predict conversion to FEP in CHR cohorts 
[e.g., Ref. (37)], from a biomarker perspective, it could be argued 
that dysfunction in lateral temporal lobe regions (and their 
associated networks) is a better predictor of conversion to FEP 
than hippocampal dysfunction. We will examine the evidence of 
this in the next section.
Is Conversion to Psychosis Associated 
With Dysfunction in Just One or Both 
Temporal Networks?
At presentation, neuroimaging studies have identified a number 
of neurofunctional, neuroanatomical, and neurochemical 
changes in CHR cohorts relative to age-matched healthy controls. 
Furthermore, there is emerging evidence that neurobiological 
changes in temporal lobe regions at the CHR stage are 
directly related to APS. A small number of prospective and 
longitudinal neuroimaging studies have attempted to identify 
neural or biomarkers that predict conversion to psychosis in 
CHR cohorts. Multisite studies in CHR cohorts investigating 
volumetric changes associated with conversion to psychosis have 
reported different findings; one study reports that conversion to 
psychosis in CHR cohorts is associated with reduced left anterior 
hippocampal volume at presentation (15), while a second study 
reports that conversion is associated with reduced gray matter 
volume in prefrontal rather than temporal regions (89).
Functional MRI studies in CHR cohorts have reported that 
conversion to psychosis is associated with increased activation in 
the brainstem (midbrain/basilar pons) and the left hippocampus 
FIGURE 3 | Example of connectivity findings in CHR samples. (A) Increased 
connectivity between hippocampus and striatum, and midbrain and striatum 
(Modinos, et al., 2019, 96). (B) Decreased connectivity between STG and 
prefrontal regions (89).
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(10), the left STG, IFG, and caudate (23), and altered VTA–striatal 
effective connectivity (Modinos et al., 2019). PET studies using 18 
Fluorodopa (18F-DOPA) also report increased striatal (12–14) 
and midbrain (10) presynaptic dopamine synthesis in CHR cases 
at presentation that later convert to psychosis. Two magnetic 
resonance spectroscopy (MRS) studies report increased striatal 
(98) and hippocampal (20) glutamate levels in CHR conversion 
cases, although another study reports that CHR individuals have 
significantly lower hippocampal Glx (combined glutamate and 
glutamine) levels relative to both healthy volunteers and FEP 
patients (99).
While these findings are broadly consistent with models that posit 
altered neurobiology in lateral/medial lobe regions and associated 
networks, not all prospective/longitudinal studies in CHR cohorts 
implicate the temporal lobes. For example, a recent study by Cao 
et al. (88) reports that CHR individuals show an intrinsic abnormality 
in cerebellar–thalamic–frontal cortical circuitry associated with 
disorganization symptoms that is significantly more pronounced 
among converters than nonconverters. Moreover, multivariate 
approaches to CHR outcome classification implicate a much wider 
range of cortical, cerebellar, and subcortical regions [e.g., Ref. (100)] 
making it difficult to attribute emergent APS to any specific network.
Together, these neuroimaging findings suggest that conversion 
to psychosis in CHR cohorts is associated with a wide range 
of structural, functional, and neurochemical alterations, i.e., 
altered structure and function in hippocampal, prefrontal, lateral 
temporal, midbrain, striatal, thalamic, and cerebellar regions as 
well as increased mesolimbic dopamine function and altered 
hippocampal and striatal glutamate/glutamine function. On 
the basis of these diverse neurobiological findings, it is difficult 
to attribute conversion to psychosis in CHR groups to a discrete 
region, network, or circuit. Moreover, there is some evidence from 
rodent models that disrupted hippocampal development can lead 
to neurophysiological abnormalities across several cortical regions, 
most prominently observed in prefrontal cortex circuits (66). We 
speculate, therefore, that hippocampal/MTL pathophysiology 
is seen early in development, but as the brain matures with this 
abnormality, other circuits, perhaps involving the lateral temporal 
and prefrontal cortex, become dysregulated. Currently, there are no 
studies that directly test this chronological prediction in humans 
although a cross-sectional study by Benetti and colleagues does link 
altered hippocampal and prefrontal function in CHR subject (101). 
Alternatively, in schizophrenia, there may be a pathological process 
playing out across multiple cortical and subcortical circuits, and 
the hippocampal–striatal–midbrain circuit may be where it is most 
evident (and possibly most severe) in the CHR/prodromal stage.
In summary, while there is evidence for emerging dysfunction in 
a range of cortical and subcortical regions in CHR cohorts, altered 
structure and function in medial and lateral temporal lobe regions, 
along with prefrontal regions, appear to be seen to a greater extent 
in CHR cases that convert to psychosis. While the evidence remains 
equivocal, several imaging studies adopting whole brain analytical 
approaches support this view [e.g., Refs. (10, 15, 21, 23, 24, 89)] 
and recent connectivity studies in large CHR data sets show that 
lateral temporal (28) and prefrontal cortex (88) disconnectivity are 
particularly associated with conversion to psychosis. Intriguingly, 
analysis of speech in CHR cohorts (a function strongly related to 
lateral temporal, frontal, and parietal lobe function) (81) shows that 
reduced semantic coherence and syntactic complexity predicted 
later psychosis development with 100% accuracy, outperforming 
classification from clinical interviews (102). These findings were 
cross-validated in a second larger cohort using a speech automated 
machine-learning speech classifier—comprising decreased semantic 
coherence, greater variance in that coherence, and reduced usage of 
possessive pronouns. This classifier had 83% accuracy in predicting 
psychosis onset (103). These findings are broadly in line with 
earlier factor analytical studies for CHR symptom dimensions that 
report disorganized thought and speech as predictor of subsequent 
conversion to psychosis (37). More generally, the neuropsychological 
data in CHR cohorts suggests that later conversion to psychosis is 
associated with marked deficits in verbal fluency, processing speed 
and memory domains (1), cognitive functions likely to rely on 
frontal, lateral temporal, and hippocampal activity and connectivity.
Based on the studies discussed here, several questions remain 
about emerging brain network dysfunction in CHR cohorts. 
Firstly, is dysfunction in both lateral and medial temporal 
networks necessary for the emergence of a CHR for psychosis or 
is dysfunction in one or the other network sufficient? Secondly, 
what is the pathological relationship between dysfunction in 
these temporal lobe networks? Third, do alterations in volume, 
function, and connectivity in these regions/networks occur at 
the same time, or is there a chronological progression related 
to illness stage, symptom severity, and risk (conversion) for 
psychosis? Fourth, is dysfunction in these networks related to 
different pathological or etiological processes?
Studies investigating schizotypal personality disorder (SPD) 
might provide preliminary insight regarding the first question, 
as SPD is conceded to represent an intermediate schizophrenia-
spectrum phenotype (104). Evidence for temporal and frontal lobe 
alterations appears to be fairly robust in SPD samples. Similar to 
findings in CHR samples [e.g., Ref. (90)], investigations utilizing 
DTI in SPD populations report reduced fractional anisotropy in the 
uncinated fasciculus (but not in the cingulum) (105), reduced frontal 
and temporal lobe gray matter (106–109), and reduced temporal lobe 
gray matter thickness (106). Probabilistic tractography approaches 
also indicate that healthy individuals higher on psychometric 
schizotypy traits present with lower fractional anisotropy in the 
inferior fronto-occipital fasciculus overall (106). A recent fMRI 
study in an SPD population, investigating symptom clusters, 
reported that higher resting-state functional connectivity between 
the frontal and lateral temporal cortex was linked to positive and 
disorganized dimensions, respectively (110).
However, in SPD populations, there appears to be less evidence 
in line with rodent models of psychosis and findings in CHR 
cohorts. One recent study has shown that participants that score 
highly on measures of schizotypal personality traits (healthy 
participants with psychotic-like experiences) show higher rCBF in 
the right hippocampus compared to low-scoring individuals (111), 
although no differences were observed in midbrain or striatum. 
However, results from one early single-photon emission computed 
tomography (SPECT) study suggested relatively greater presynaptic 
dopamine release in the striatum of SPD individuals relative to 
healthy controls, similar to levels observed in patients with remitted 
schizophrenia (112).
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Taken together, studies in SPD cohorts seem to provide more 
evidence for lateral temporal and frontal lobe dysfunction than they 
do for dysfunction in a hippocampal–striatal–midbrain circuit, 
although this may be because far less research has been conducted 
that explicitly examines the hippocampal–striatal–midbrain circuit 
in psychometric schizotypy/SPD populations (110–113).
Regarding the final question about etiology, there are some 
interesting clues from previous research. Although increased striatal 
dopamine function has been reported in CHR cohorts (12–14, 114), 
no increase in striatal dopamine synthesis was seen in a cohort of 
nonclinical voice hearers (114). However, increased lateral temporal 
activity while experiencing voices has been reported in nonclinical 
voice hearers (115). This finding suggests that dysfunction in the 
STG and wider frontal and temporal networks, which underlies the 
experience of auditory verbal hallucinations (10), is not necessarily 
related to elevated striatal dopamine function, suggesting the 
possibility of a different etiological pathway. However, it should 
be noted that a recent PET study by Cassidy et al. (116) reported 
a relationship between striatal dopamine release and auditory 
perceptual disturbances and outlined a novel dopamine-dependent 
mechanism for perceptual modulation that may confer vulnerability 
to hallucinations in hyperdopaminergic states underlying psychosis.
CONCLUSIONS AND FUTURE WORK
The literature discussed here strongly suggests that altered 
structure, function, and connectivity in both the medial and 
lateral temporal lobe play a key role in the development of CHR 
states and psychosis. Critically, increased rCBF and neural 
activity in the hippocampus seems to be a well-established factor 
in CHR populations, suggesting that abnormalities are present at 
the earliest stages of the condition. Further, studies have linked 
increased hippocampal glutamate and rCBF with conversion 
to psychosis, in line with rodent models suggesting that 
abnormalities in the hippocampus lead to dopamine dysfunctions 
and abnormal salience processing. While the etiology behind 
these hippocampal changes is not clear at this stage, immune/
inflammatory responses appear to be a factor (117, 118).
Studies also report functional and volumetric abnormalities 
in the lateral temporal lobe and associated frontal–temporal and 
parietal language networks, possibly linked to the disorganized 
language and speech symptoms during the CHR stage. However, 
while disorganized speech and language symptoms appear to 
be a strong predictor of conversion to FEP in CHR cohorts, 
supported by recent findings using speech algorithms, findings 
from neuroimaging studies are far less equivocal, i.e., there is no 
clear evidence that lateral temporal lobe-centered networks are 
the best predictor of conversion to FEP.
While the findings discussed here strongly implicate 
hippocampal, lateral temporal lobe, and broader network 
dysfunction in CHR samples, the specific mechanisms or 
chronology of emerging brain network dysfunction in CHR 
cohorts remains unclear. Hippocampal abnormalities (leading to 
dopamine dysregulation) could lead to widespread abnormalities 
in other regions, particularly other (local) temporal lobe 
regions, which then lead to psychosis conversion. Alternatively, 
psychosis progression might be linked to widespread neural 
circuit abnormalities (with hippocampal dysfunction being most 
prominent). More sophisticated multimodal longitudinal studies 
are needed to test these alternative possibilities.
In addition to more sophisticated mechanistic studies, those 
utilizing novel pharmacological agents could provide valuable 
insights into whether potentially blocking increases in extracellular 
glutamate in MTL regions can ameliorate hypermetabolism and 
atrophy in CHR cohorts. A recent rodent study reported that 
glutamate dysregulation in the CA1 region of the hippocampus 
initiated the transition to syndromal psychosis (19). Investigating 
whether the administration of glutamate regulating drugs in CHR 
samples would normalize hippocampal hypermetabolism and 
prevent symptomatic and pathological progression may help to 
elucidate the mechanistic chronology during emerging psychosis.
Finally, it needs to be noted that schizophrenia is symptomatically 
heterogeneous and that symptoms and clinical outcomes in 
prodromal cases are even more heterogeneous. This may be because 
dysfunction in different neural circuits and neurotransmitter systems 
may predominate in different subtypes and stages of the disease, 
which, as defined, represents only a final common syndrome.
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